Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor

被引:58
|
作者
Cotte, N
Balestre, MN
Phalipou, S
Hibert, M
Manning, M
Barberis, C
Mouillac, B
机构
[1] CNRS, INSERM, Ctr Pharmacol Endocrinol, Unite 469, F-34094 Montpellier 5, France
[2] Fac Pharm Strasbourg, Lab Pharmacochim Commun Cellulaire, F-67401 Illkirch Graffenstaden, France
[3] Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA
关键词
D O I
10.1074/jbc.273.45.29462
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To improve our understanding of the functional architecture of G protein-coupled receptors, we have taken advantage of differences among mammalian species in ligand binding to search for the rat versus human selectivity determinants of the V2 vasopressin receptor and of its peptide ligands. Our data indicate that residue 2 of species-selective peptide antagonists such as d(CH(2))(5)-[D-Ile(2),Ile(4),Tyr-NH(2)(9)]arginine vasopressin controls their rat versus human selectivity. For species-selective agonists such as desmopressin, residues 1 and 8 modulate the binding selectivity. Among residues different between rat and human V2 receptors, those localized in the upper part of the human V2 receptor have been substituted with their rat V2 homologs. Pharmacological analysis of mutant receptors revealed that residues 202 and 304 fully control the species selectivity of the discriminating antagonists in an independent and additive manner. A third residue (position 100) is necessary to observe an equivalent phenomenon for the discriminating agonists. The substitution of these three residues does not modify the affinity of the nonselective agonists and antagonists. In conclusion, extracellular loops and the top of the transmembrane domains of V2 vasopressin receptors may provide the molecular basis for peptide ligand-binding species selectivity. Very few residues in these regions may control the binding mode of both agonists and antagonists.
引用
收藏
页码:29462 / 29468
页数:7
相关论文
共 50 条
  • [1] Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor.
    Cotte, N
    Balestre, MN
    Phalipou, S
    Hibert, M
    Manning, M
    Barberis, C
    Mouillac, B
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R709 - R709
  • [2] The vasopressin V2 receptor:: molecular basis of the nephrogenic diabetes insipidus and identification of residues responsible for binding selectivity
    Morin, D
    Cotte, N
    Phalipou, S
    Balestre, MN
    Ala, Y
    Sabatier, N
    Jard, S
    Vargas, R
    Antignac, C
    Déchaux, M
    Arthus, M
    Lonergan, M
    Turner, MS
    Bichet, DG
    Hendy, GN
    Alonso, G
    Manning, M
    Hibert, M
    Mouillac, B
    Barberis, C
    HYDRATION THROUGHOUT LIFE, 1998, : 215 - 221
  • [3] Identification of novel selective V2 receptor non-peptide agonists
    Del Tredici, Andria L.
    Vanover, Kim E.
    Knapp, Anne E.
    Bertozzi, Sine M.
    Nash, Norman R.
    Burstein, Ethan S.
    Lameh, Jelveh
    Currier, Erika A.
    Davis, Robert E.
    Brann, Mark R.
    Mohell, Nina
    Olsson, Roger
    Piu, Fabrice
    BIOCHEMICAL PHARMACOLOGY, 2008, 76 (09) : 1134 - 1141
  • [4] Vasopressin V2 receptor antagonists
    Wong, LL
    Verbalis, JG
    CARDIOVASCULAR RESEARCH, 2001, 51 (03) : 391 - 402
  • [5] Vasopressin V2 receptor antagonists
    Verbalis, JG
    JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2002, 29 (01) : 1 - 9
  • [6] Recent discovery and development of non-peptide vasopressin V2 receptor agonists
    Kondo, K
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2002, 12 (08) : 1249 - 1258
  • [7] Pyridobenzodiazepines:: A novel class of orally active, vasopressin V2 receptor selective agonists
    Failli, AA
    Shumsky, JS
    Steffan, RJ
    Caggiano, TJ
    Williams, DK
    Trybulski, EJ
    Ning, XP
    Lock, Y
    Tanikella, T
    Hartmann, D
    Chan, PS
    Park, CH
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (04) : 954 - 959
  • [8] Structurally novel V2-selective and dual V1A/V2 vasopressin receptor antagonists.
    Dyatkin, AB
    Maryanoff, BE
    Hoekstra, WJ
    Hlasta, DJ
    Andrade-Gordon, P
    DeGaravilla, L
    Demarest, K
    Gunnet, J
    Look, R
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 223 : A93 - A93
  • [9] Bridged bicyclic vasopressin receptor antagonists V2-selective or dual V1a/V2 activity
    Dyatkin, AB
    Hoekstra, WJ
    Hlasta, DJ
    Andrade-Gordon, P
    de Garavilla, L
    Demarest, KT
    Gunnet, JW
    Hagemann, W
    Look, R
    Maryanoff, BE
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (21) : 3081 - 3084
  • [10] COMPARISON OF SELECTIVE ARGININE VASOPRESSIN V1 AND V2 RECEPTOR ANTAGONISTS ON BURN SHOCK IN THE RAT
    SUN, K
    LIN, BC
    WANG, CH
    ZHU, HN
    CARDIOVASCULAR RESEARCH, 1991, 25 (04) : 265 - 269